Everpure (P)

NYSEInformation TechnologyComputer HardwareSnapshot 2026-10-23

$123.33+1.76%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Everpure’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+18.1% · beyond scale

+10% or more+5%0%−5%−10% or less

3.55 → 4.19 EPS · FY ending Feb 1, 2028 · 13 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 13 to 13; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q3
Revenue	—	1.33B
EPS	—	0.77
FY 2027 · Annual
Revenue	—	5.05B
EPS	—	2.783
Revenue growth	37%–38%	—
FY 2028 · Annual
Revenue	—	6.91B
EPS	—	4.193

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
FY27 operating margin near 32.5%	A primary condition in Everpure's published investment case. The stated target is >= 29%.	Improving	FY27 operating margin falls below 29%	Operating margin: 5.33% FY2027-Q2; GAAP. Published target: >= 29%. Target period is not explicitly aligned with this observation. Source published Sep 4, 20265.3255 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 2, 2026 Source: company_financial_results. Reference: bd81691d-6805-4ede-8123-003ee692f246. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating income increased from $19.9M in 2027-Q1 to $63.2M in 2027-Q2. Management raised FY27 non-GAAP operating income guidance from $820M-$860M to $940M-$960M, indicating improved profitability expectations. The trajectory is delivering with rising operating income and upward guidance. Delivery assessment Oct 24, 2026
Q2 FY27 revenue between $1.095B and $1.105B	A supporting condition in Everpure's published investment case. The stated target is between $1.095 billion and $1.105 billion.	Intact	Q2 FY27 revenue falls below $1.095 billion	Revenue: $1.186B FY2027-Q2; GAAP. Published target: between $1.095 billion and $1.105 billion. Target period is not explicitly aligned with this observation. Source published Sep 4, 20261,185,898,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 2, 2026 Source: company_financial_results. Reference: bd81691d-6805-4ede-8123-003ee692f246. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management set Q2FY27 revenue guidance at $1.095B to $1.105B and actual revenue was $1.186B, exceeding guidance. This shows delivery above the stated target and confirms focus on quarterly revenue milestones. Delivery assessment Oct 24, 2026
FY27 revenue at least $4.41 billion	A primary condition in Everpure's published investment case. The stated target is >= $4.41 billion.	Intact	FY27 revenue falls below $4.41 billion	Revenue: $1.186B FY2027-Q2; GAAP. Published target: >= $4.41 billion. Target period is not explicitly aligned with this observation. Source published Sep 4, 20261,185,898,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q2 · Period ending Aug 2, 2026 Source: company_financial_results. Reference: bd81691d-6805-4ede-8123-003ee692f246. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $861M in 2026-Q2 to $1.19B in 2026-Q3 (+38%). Management raised FY27 revenue guidance from $4.41B-$4.51B to $5.03B-$5.07B, reflecting strong demand and momentum. The trajectory is delivering with accelerating revenue growth and upward guidance revisions. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-02-01 · fmp

FY2028 EPS$4.19

$3.00 → $4.19 · observed estimates

FY2028 revenue$6.91B

$5.16B → $6.91B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.00	$5,160,932,076	13 / 15
2026-07-25	$3.00	$5,160,932,076	13 / 15
2026-07-26	$3.00	$5,160,932,076	13 / 15
2026-07-27	$3.00	$5,160,932,076	13 / 15
2026-07-28	$3.00	$5,160,932,076	13 / 15
2026-07-29	$3.00	$5,160,932,076	13 / 15
2026-07-30	$3.00	$5,160,932,076	13 / 15
2026-07-31	$3.00	$5,160,932,076	13 / 15
2026-08-01	$3.00	$5,160,932,076	13 / 15
2026-08-02	$3.00	$5,160,932,076	13 / 15
2026-08-03	$3.00	$5,160,932,076	13 / 15
2026-08-04	$3.00	$5,160,932,076	13 / 15
2026-08-05	$3.00	$5,160,932,076	13 / 15
2026-08-06	$3.00	$5,160,932,076	13 / 15
2026-08-07	$3.00	$5,160,932,076	13 / 15
2026-08-08	$3.00	$5,160,932,076	13 / 15
2026-08-09	$3.00	$5,160,932,076	13 / 15
2026-08-10	$3.00	$5,160,932,076	13 / 15
2026-08-12	$3.00	$5,160,932,076	13 / 15
2026-08-13	$3.00	$5,160,932,076	13 / 15
2026-08-14	$3.00	$5,160,932,076	13 / 15
2026-08-15	$3.00	$5,160,932,076	13 / 15
2026-08-16	$3.00	$5,160,932,076	13 / 15
2026-08-17	$3.00	$5,160,932,076	13 / 15
2026-08-18	$3.00	$5,160,932,076	13 / 15
2026-08-19	$3.00	$5,160,932,076	13 / 15
2026-08-20	$3.07	$5,215,005,549	13 / 15
2026-08-21	$3.07	$5,222,947,655	13 / 15
2026-08-22	$3.09	$5,242,952,918	13 / 15
2026-08-23	$3.09	$5,242,952,918	13 / 15
2026-08-24	$3.09	$5,242,952,918	13 / 15
2026-08-25	$3.09	$5,242,952,918	13 / 15
2026-08-26	$3.09	$5,242,952,918	13 / 15
2026-08-27	$3.09	$5,242,952,918	13 / 15
2026-08-28	$3.09	$5,242,952,918	13 / 15
2026-08-29	$3.55	$6,137,431,051	13 / 15
2026-08-30	$3.55	$6,137,431,051	13 / 15
2026-08-31	$3.55	$6,137,431,051	13 / 15
2026-09-01	$3.55	$6,137,431,051	13 / 15
2026-09-02	$3.55	$6,182,062,630	13 / 15
2026-09-03	$3.55	$6,182,062,630	13 / 15
2026-09-04	$3.55	$6,182,062,630	13 / 15
2026-09-05	$3.55	$6,182,064,709	13 / 15
2026-09-06	$3.55	$6,182,064,709	13 / 15
2026-09-07	$3.55	$6,182,064,709	13 / 15
2026-09-08	$3.55	$6,182,064,709	13 / 15
2026-09-09	$3.55	$6,182,064,709	13 / 15
2026-09-10	$3.55	$6,182,064,709	13 / 15
2026-09-11	$3.55	$6,182,064,709	13 / 15
2026-09-12	$3.55	$6,182,064,709	13 / 15
2026-09-13	$3.55	$6,182,064,709	13 / 15
2026-09-14	$3.55	$6,182,064,709	13 / 15
2026-09-15	$3.55	$6,182,064,709	13 / 15
2026-09-16	$3.55	$6,182,064,709	13 / 15
2026-09-17	$3.55	$6,182,064,709	13 / 15
2026-09-18	$3.55	$6,182,064,709	13 / 15
2026-09-19	$3.55	$6,182,064,709	13 / 15
2026-09-20	$3.55	$6,185,057,709	13 / 15
2026-09-21	$3.55	$6,185,057,709	13 / 15
2026-09-22	$3.55	$6,185,057,709	13 / 15
2026-09-23	$3.55	$6,185,057,709	13 / 15
2026-09-24	$3.55	$6,185,057,709	13 / 15
2026-09-25	$4.17	$6,834,221,644	13 / 14
2026-09-26	$4.19	$6,914,451,386	13 / 14
2026-09-27	$4.19	$6,914,451,386	13 / 12
2026-09-28	$4.19	$6,914,451,386	13 / 12
2026-09-29	$4.19	$6,914,451,386	13 / 12
2026-09-30	$4.19	$6,914,451,386	13 / 12
2026-10-01	$4.19	$6,914,451,386	13 / 13
2026-10-02	$4.19	$6,914,451,386	13 / 13
2026-10-03	$4.19	$6,914,451,386	13 / 13
2026-10-04	$4.19	$6,914,451,386	13 / 13
2026-10-05	$4.19	$6,914,435,596	13 / 13
2026-10-06	$4.19	$6,914,451,386	13 / 13
2026-10-07	$4.19	$6,914,451,386	13 / 13
2026-10-08	$4.19	$6,914,451,386	13 / 13
2026-10-09	$4.19	$6,914,451,386	13 / 13
2026-10-10	$4.19	$6,914,451,386	13 / 13
2026-10-11	$4.19	$6,914,451,386	13 / 13
2026-10-12	$4.19	$6,914,451,386	13 / 13
2026-10-13	$4.17	$6,911,214,544	12 / 13
2026-10-14	$4.17	$6,911,214,544	12 / 13
2026-10-15	$4.17	$6,911,214,544	13 / 13
2026-10-16	$4.17	$6,911,214,544	13 / 13
2026-10-17	$4.17	$6,911,214,544	13 / 13
2026-10-18	$4.17	$6,911,214,544	13 / 13
2026-10-19	$4.17	$6,911,214,544	13 / 13
2026-10-20	$4.19	$6,911,198,754	13 / 13
2026-10-21	$4.19	$6,911,198,754	13 / 13
2026-10-22	$4.19	$6,911,198,754	13 / 13
2026-10-23	$4.19	$6,911,198,754	13 / 13
2026-10-24	$4.19	$6,911,198,754	13 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	15	5	1
2026-06-01	14	5	1
2026-07-01	14	5	1
2026-08-01	18	5	1
2026-09-01	18	1	1
2026-10-01	18	1	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 18 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimOct 12 · prior Aug 13

$150.00 → $215.00+43.3%

NeedhamOct 8 · prior Sep 24

$150.00 → $185.00+23.3%

BarclaysSep 25 · prior Aug 28

$110.00 → $132.00+20.0%

$0$118.25$236.50

3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

FY27 operating margin near 32.5%Operating margin: 5.33%
Q2 FY27 revenue between $1.095B and $1.105BRevenue: $1.186B
FY27 revenue at least $4.41 billionRevenue: $1.186B

Next proof point

Dec 1, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-42.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Everpure outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

P is a high-growth Tech business with a speculative growth profile, rather than an established, consistently profitable compounder. Its multi-year view remains intact this month, supported by strong recent execution, though the evidence confidence is medium and risk is elevated.

What's priced into Everpure

P is expensive versus peers, with a 1.84 premium measure and a 0.29 expectations gap; the valuation model has low confidence. The evidence labels the pricing as unjustified, but fragility is low because expensive valuation is not paired with weak fundamentals and turbulent conditions.

What the fundamentals likely do

Near term, revenue momentum and management guidance have improved: revenue grew from $861 million to $1.19 billion, and FY27 revenue and operating income guidance both rose. Recent earnings beats and delivery above the Q2FY27 revenue target support execution, although the business remains loss-making overall and a guidance cut would be a meaningful risk.

What Everpure hinges on

Over the next several quarters, the thesis depends on continued revenue growth and progress toward higher operating income guidance. A guidance cut or renewed execution trouble would weaken the case, while rate cuts and continued earnings strength from Tech peers could support the sector backdrop.